NASDAQ
8.56USD
+0.28 (+3.38%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
671.5M
P/E
—
EPS
—
Beta
1.50
52W range
6.13-14.96
Day range
8.35–8.57
Open
8.35
Prev close
8.28
Volume
1.2M
Avg volume
1.3M
Dividend
0.00
IPO
2010-05-13
https://seekingalpha.com/article/4914604-credo-dont-chase-this-winner-over-the-cliff-downgrade-to-hold · 6/12/2026+1.00
https://www.zacks.com/stock/news/2921047/cormedix-crmd-q1-earnings-and-revenues-beat-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2921047 · 5/14/2026+0.60
https://www.zacks.com/stock/news/2822064/will-crmd-s-bearish-2026-view-impact-defencath-s-long-term-adoption?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2822064 · 1/23/2026-0.20
https://www.zacks.com/stock/news/2814989/are-investors-undervaluing-cormedix-crmd-right-now?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_2-2814989 · 1/9/2026+1.00
https://www.zacks.com/stock/news/2801663/does-cormedix-crmd-have-the-potential-to-rally-68-74-as-wall-street-analysts-expect?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|consensus_price_target-2801663 · 12/9/2025
https://seekingalpha.com/article/4842516-cormedix-inc-crmd-q3-2025-earnings-call-transcript · 11/12/2025+0.00
https://seekingalpha.com/article/4832903-cormedix-strong-buy-after-strong-developments-strategy-before-earnings · 10/24/2025+1.00
https://www.zacks.com/stock/news/2773129/wall-street-analysts-see-a-68-59-upside-in-cormedix-crmd-can-the-stock-really-move-this-high?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|consensus_price_target-2773129 · 10/21/2025+0.80
https://seekingalpha.com/article/4816662-cormedix-the-undervalued-breakthrough · 8/26/2025+1.00
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
